Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

137 results about "New mutation" patented technology

New mutation. new mu·ta·tion. redundant term for a heritable trait present in the offspring but in neither parent, that is, not a preexisting mutant form inherited.

Probes, method and chip for detecting alpha and/or beta-thalassemia mutation based on whole-gene capture sequencing and application of such probes, such method and such chip

ActiveCN106591441AEnables detection of deletions in large regionsMicrobiological testing/measurementDNA/RNA fragmentationBeta thalassemiaNew mutation
The invention provides primers, a method and a chip for detecting alpha and/or beta-thalassemia point mutation and deletion mutation based on whole-gene capture sequencing and application of such primers, such method and such chip. The primers, the method, the chip and application thereof have the advantages that through designing of capture probes, relevant genes involved in alpha-thalassemia and beta-thalassemia are enriched and all mutation information including SNP and indel in full-length sequences of genes is detected; through addition of autosome, X-chromosome and Y-chromosome regions as well as upstream and downstream regions of coded genes as references, structure variations such as SNV and CNV are detected; compared with existing various hotspot mutation site detection technologies, the method is capable of detecting hotspot mutation information as well as some rare mutations and undiscovered new mutation types to detect and analyze full-length sequence specificity of target genes, fully covers the mutation types and makes up the defect that a conventional detection method easily causes missing detection of low-frequency mutations and rare mutations greatly.
Owner:SHENZHEN E GENE TECH

CYP4V2 gene mutant and application thereof

The invention provides a CYP4V2 gene mutant and an application thereof, belonging to the field of medical molecular biology. The invention applies to protect the separated new CYP4V2 mutant pathogenic gene of Bietti crystalline dystrophy (BCD) and a mutant polypeptide thereof on the one hand. The gene is characterized in that compared with genes coding wild type CYP4V2 proteins, such as nucleotide sequences shown in SEQ ID NO:1, a nucleic acid sample of the mutant pathogenic gene has the characteristic that the (1027) basic group suffers from T>G mutation. Based on the separated pathogenic mutant gene, the invention further provides a method, system and kit for screening biological samples susceptible to BCD as well as a method for screening medicines for treating or preventing BCD.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA

Attenuated streptococcus suis vaccines and methods of making and use thereof

The present invention provides attenuated S. suis strains that elicit an immune response in animal S. suis, compositions comprising said strains, methods of vaccination against S. suis, and kits for use with such methods and compositions. The invention further provides novel, mutagenically-induced mutations in S. suis genes, which are useful in the production of novel attenuated S. suis bacterial strains.
Owner:BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC

New mutant disease-causing gene of Alport syndrome, encoded protein and application thereof

In the invention, two new mutations of two disease-causing genes relative to Alport syndrome are identified through an exon sequencing method. The inventor, by employing two ATS families as research objects, particularly performs exon sequencing and comparison respectively to diseased individuals and non-diseased individuals in the two ATS family and finds a frame shift deletion mutation (c.3213delA,p.Lys1071fs*5) on a COL4A4 gene of one family and a frame shift deletion mutation (c499delC,p.Pro167Glnfs*36) on a COL4A5 gene of the other family, wherein the two frame shift deletion locus are actual disease-causing locus of the two families. On the basis of above, the invention provides a mutant COL4A4 gene and a mutant COL4A5 gene, encoded protein and application thereof and includes carriers, host cells and kits of the mutant COL4A4 gene and / or the mutant COL4A5 gene. By means of the mutant COL4A4 gene and / or the mutant COL4A5 gene, molecular diagnosis and diseasing risk evaluation of the Alport syndrome can be carried out. The two mutant genes and the encoded proteins thereof also can be used as medicine targets for treating the Alport syndrome.
Owner:石家庄华大医学检验实验室有限公司 +1

Primer composition, kit and method for detecting susceptibility gene mutation of hemochromatosis and hepatolenticular degeneration

The invention discloses a primer composition, a kit and a method for detecting susceptibility gene mutation of hemochromatosis and hepatolenticular degeneration. The invention firstly discloses the primer composition for detecting the susceptibility gene mutation of hemochromatosis and hepatolenticular degeneration. The invention further discloses the kit containing the primer composition and themethod for detecting the susceptibility gene mutation of hemochromatosis and hepatolenticular degeneration. The method for detecting the susceptibility gene mutation of hemochromatosis and hepatolenticular degeneration integrates gene mutation and copy number mutation information of all exon and intron cleavage regions of susceptibility genes of hemochromatosis and hepatolenticular degeneration inChinese population, and has the advantages of high detection flux, high specificity and sensitivity, 100% of sequencing coverage, more than 30x of depth, clear and objective gene detection result interpretation, good accuracy and repeatability, low cost, simple operation and easy popularization; and the method can not only detect known high-incidence mutation, but also discover new mutation sites.
Owner:BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV

Gene relevant mutational site of mitochondrial deaf and application

The invention belongs to the field of genomics, particularly relating to the deaf relevant mutation 12201 T>C of mitochondrial gene and application. The sequence in which the deaf relevant mutation 12201 T>C of mitochondrial gene of the invention is positioned has the structure of sequence 1. The invention can adopt the deaf relevant mutation of mitochondrial gene to preferentially detect the mitochondria mutational site of deaf patients, which is favourable for eliminating or diagnosing deaf caused by mitochondrial gene mutation; a diagnostic probe prepared by deaf relevant new mutation of the mitochondrial gene, a primer for introducing mutation to cause enzyme cutting site and a kit are adopted to conveniently and quickly screen deaf relevant to mitochondria. The invention provides the reference base for function change caused by gene mutation and provides a favorable chance for disclosing the molecular mechanism of deaf caused by the mitochondria DNA mutation.
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV

Method for searching for new mutation/SNP locus based on double-nucleotide pyrosequeneing-by-synthesis

The invention discloses a method for searching for a new mutation/SNP locus based on double-nucleotide pyrosequeneing-by-synthesis. According to the method, PCR is conducted on the genomic DNAs of a known sequence sample and a mixed sample, pyrosequeneing is conducted on obtained single-stranded PCR products according to a specific double-nucleotide adding method, each sample acquires two groups of double-nucleotide pyrosequeneing-by-synthesis information, and correction is conducted; the two groups of corrected mixed sample sequencing information are compared with the two groups of corrected known sequence sample sequencing information; if neither the two groups of mixed sample sequencing information nor the two groups of known sequence sample sequencing information are changed, it is indicated that the mixed sample sequencing information is consistent with the known sequence sample sequencing information, and no new mutation/SNP locus exists; if the mixed sample sequencing information is different from at least one of the two groups of known sequence sample sequencing information, it is indicated that the mixed sample sequencing information is not totally consistent with the known sequence sample sequencing information, and it shows that a new mutation/SNP locus exists.
Owner:SOUTHEAST UNIV

BRCA2 g. 32338309A>G mutant and application thereof in breast cancer assisted diagnosis

The invention discloses a BRCA2 g. 32338309A>G mutant and application thereof in breast cancer assisted diagnosis. Compared with the sequence of normal BRCA2 genes, the sequence of the BRCA2 g. 32338309A>G mutant has g. 32338309A>G locus mutation. The invention further discloses a specific primer for detecting the BRCA2 g. 32338309A>G mutant, a kit containing the specific primer, and application of the BRCA2 g. 32338309A>G mutant in breast cancer assisted diagnosis. The BRCA2 g. 32338309A>G mutant provides a new mutant sit of breast cancer pathogenesis to assist breast cancer diagnosis.
Owner:WUXI NO 5 PEOPLES HOSPITAL

Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof

The invention belongs to the field of biochemistry, molecular biology and neurosciences, and relates to a novel alpha O-conotoxin GeXIVA mutant and a pharmaceutical composition and application thereof. Specifically, the invention relates to a separated polypeptide. The amino acid sequence of the polypeptide is obtained by removing one or more amino acids in a mother sequence or replacing one or more amino acids in the mother sequence with the same number of L-type amino acids or D-type amino acids, wherein the mother sequence is SEQ ID NO:1, SEQ ID NO:62 or SEQ ID NO:63; and the polypeptide has an activity of blocking alpha9alpha10nAChR. The polypeptide disclosed by the invention can specifically block the alpha9alpha10nAChR, and has a good application prospect in the aspects of preparinganalgesic drugs, drugs for treating related mental diseases and cancers, neuroscience tool drugs and the like.
Owner:HAINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products